

Cã;rmino Antonio de Souza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1752227/publications.pdf>

Version: 2024-02-01

241
papers

6,411
citations

116194

36
h-index

84171

75
g-index

247
all docs

247
docs citations

247
times ranked

7409
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of a physiotherapeutic protocol in cardiorespiratory, muscle strength, aerobic capacity and quality of life after hematopoietic stem cell transplantation. <i>Hematology, Transfusion and Cell Therapy</i> , 2023, 45, 154-158.	0.1	1
2	Transplante em Linfoma Difuso de Grandes C�lulas B. <i>Brazilian Journal of Transplantation</i> , 2022, 25, .	0.1	0
3	Transplant in Diffuse Large B-Cell Lymphoma. <i>Brazilian Journal of Transplantation</i> , 2022, 25, .	0.1	0
4	Trasplante en Linfoma Difuso de C�lulas B Grandes. <i>Brazilian Journal of Transplantation</i> , 2022, 25, .	0.1	0
5	Single nucleotide variants in immune-response genes and the tumor microenvironment composition predict progression of mantle cell lymphoma. <i>BMC Cancer</i> , 2021, 21, 209.	1.1	5
6	How�™s going on the T-Cell Brazil project. <i>Hematology & Transfusion International Journal</i> , 2021, 9, 53-55.	0.1	0
7	Angiogenesis�™ related genetic variants alter clinical features and prognosis of diffuse large B-cell lymphoma patients. <i>Tumor Biology</i> , 2021, 43, 129-140.	0.8	3
8	The Associa��o Brasileira de Hematologia, Hemoterapia e Terapia Celular seeks the implementation of, and access to, the CAR-T cell treatment in Brazil. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, 43, S1-S2.	0.1	0
9	COVID-19 in chronic myeloid leukemia patients in Latin America. <i>Leukemia and Lymphoma</i> , 2021, 62, 3212-3218.	0.6	6
10	Head-to-head comparison between 68Ga-PSMA and 18F-FDG-PET/CT in lymphomas: a preliminary analysis. <i>Nuclear Medicine Communications</i> , 2021, 42, 1355-1360.	0.5	7
11	ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project. <i>Blood Advances</i> , 2021, 5, 640-648.	2.5	22
12	Metabolic Volume Measurements in Multiple Myeloma. <i>Metabolites</i> , 2021, 11, 875.	1.3	4
13	Single-nucleotide variants in TGFBI, TGFBR2, IL17A, and IL17F immune response genes contribute to follicular lymphoma susceptibility and aggressiveness. <i>Blood Cancer Journal</i> , 2020, 10, 97.	2.8	3
14	Efficacy and safety of pioglitazone in a phase 1/2 imatinib discontinuation trial (<scp>EDI�PIO</scp>) in chronic myeloid leukemia with deep molecular response. <i>American Journal of Hematology</i> , 2020, 95, E321-E323.	2.0	8
15	TCL-233: Angioimmunoblastic T-Cell Lymphoma: Report on 282 Cases from the Prospective International T-Cell Lymphoma Project. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S253-S254.	0.2	1
16	Computed tomography�™based skeletal segmentation for quantitative PET metrics of bone involvement in multiple myeloma. <i>Nuclear Medicine Communications</i> , 2020, 41, 377-382.	0.5	13
17	Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. <i>Lancet Haematology</i> ,the, 2020, 7, e284-e294.	2.2	78
18	An integrative microenvironment approach for follicular lymphoma: roles of inflammatory cell subsets and immune-response polymorphisms on disease clinical course. <i>Oncotarget</i> , 2020, 11, 3153-3173.	0.8	4

#	ARTICLE	IF	CITATIONS
19	99mTc-sestamibi SPECT/CT and 18F-FDG-PET/CT have similar performance but different imaging patterns in newly diagnosed multiple myeloma. <i>Nuclear Medicine Communications</i> , 2020, 41, 1081-1088.	0.5	9
20	Association between polymorphisms in angiogenesis-related genes and the prognosis of classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 366-370.	1.2	0
21	Increased risk of Hodgkin lymphoma in males with inherited T lymphocyte receptor programmed death-1 deficiency. <i>Leukemia and Lymphoma</i> , 2019, 60, 3552-3556.	0.6	2
22	Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase. <i>Hematology, Transfusion and Cell Therapy</i> , 2019, 41, 329-334.	0.1	8
23	Proposal for a Quantitative 18F-FDG PET/CT Metabolic Parameter to Assess the Intensity of Bone Involvement in Multiple Myeloma. <i>Scientific Reports</i> , 2019, 9, 16429.	1.6	26
24	Primary infratentorial diffuse large b-cell lymphoma: a challenging diagnosis in an immunocompetent patient. <i>Revista Da Associação Médica Brasileira</i> , 2019, 65, 136-140.	0.3	5
25	Management of chronic myeloid leukemia during pregnancy: a retrospective analysis at a single center. <i>Hematology, Transfusion and Cell Therapy</i> , 2019, 41, 125-128.	0.1	12
26	Role for <sc>DNA</sc> base excision repair gene variants in the prognosis of Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 186, 171-175.	1.2	0
27	Impact of SNPs/Haplotypes of <i>IL10</i> and <i>IFNG</i> on the Development of Diffuse Large B-Cell Lymphoma. <i>Journal of Immunology Research</i> , 2019, 2019, 1-8.	0.9	4
28	How I treat relapsed/refractory DLBCL patients. <i>Leukemia Research</i> , 2019, 85, S5-S6.	0.4	0
29	Cardiovascular Risk and Cardiovascular Events in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 162-166.	0.2	13
30	Characteristics of follicular and mantle cell lymphoma in Brazil: prognostic impact of clinical parameters and treatment conditions in two hospitals. <i>Hematology, Transfusion and Cell Therapy</i> , 2018, 40, 343-353.	0.1	1
31	Frequency of EBV associated classical Hodgkin lymphoma decreases over a 54-year period in a Brazilian population. <i>Scientific Reports</i> , 2018, 8, 1849.	1.6	8
32	Age and cytogenetic abnormalities. <i>Hematology, Transfusion and Cell Therapy</i> , 2018, 40, 199.	0.1	0
33	Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry. <i>Hematological Oncology</i> , 2018, 36, 189-195.	0.8	15
34	Lower socioeconomic status is independently associated with shorter survival in Hodgkin Lymphoma patients: An analysis from the Brazilian Hodgkin Lymphoma Registry. <i>International Journal of Cancer</i> , 2018, 142, 883-890.	2.3	17
35	Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1330-1338.	0.8	70
36	Fluorodeoxyglucose-positron emission tomography staging can replace bone marrow biopsy in Hodgkin's lymphoma. Results from Brazilian Hodgkin's Lymphoma Study Group. <i>Hematology, Transfusion and Cell Therapy</i> , 2018, 40, 245-249.	0.1	4

#	ARTICLE	IF	CITATIONS
37	Efficacy and Safety of Generic Imatinib Compared to Glivec in Chronic Phase - Chronic Myeloid Leukemia - a Multicenter, Observational Study. <i>Blood</i> , 2018, 132, 46-46.	0.6	4
38	B3a2 Transcript Is an Independent Factor for the Achievement of a Deep Molecular Response in Chronic Phase - Chronic Myeloid Leukemia Patients Treated with Imatinib in First-Line. <i>Blood</i> , 2018, 132, 1749-1749.	0.6	3
39	Polymorphisms in key regulator genes of the intrinsic apoptosis pathway in risk and clinical presentation of diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 911-913.	0.8	1
40	Through translational prospective study, the GSTP1 Ile105Val polymorphism emerges as prognostic marker in de novo large B-cell lymphoma patients. <i>Blood Cancer Journal</i> , 2017, 7, e560-e560.	2.8	0
41	Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 728-733.	0.2	26
42	Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2017, 39, 216-222.	0.7	8
43	VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens. <i>Blood Cancer Journal</i> , 2017, 7, e580-e580.	2.8	7
44	Association of <i>BAX</i> G(248)A and <i>BCL2</i> C(717)A polymorphisms with outcome in diffuse large B-cell lymphoma patients. <i>British Journal of Haematology</i> , 2017, 177, 650-654.	1.2	3
45	Concomitant essential thrombocythemia with JAK2 V617F mutation in a patient with chronic myeloid leukemia with major molecular response with imatinib and long-term follow-up. <i>Oncology Letters</i> , 2016, 12, 485-487.	0.8	10
46	Involvement of cranial nerves in a patient with secondary central nervous system lymphoma. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2016, 38, 158-160.	0.7	4
47	Pretransplant β_2 -Microglobulin Is Associated with the Risk of Acute Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1329-1332.	2.0	2
48	Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working Party. <i>Bone Marrow Transplantation</i> , 2016, 51, 1259-1261.	1.3	3
49	VEGF, VEGFR2 and GSTM1 Polymorphisms in Outcome of Multiple Myeloma Patients in the Thalidomide Era. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S70-S71.	0.2	0
50	Synergistic effect of KIR ligands missing and cytomegalovirus reactivation in improving outcomes of haematopoietic stem cell transplantation from HLA-matched sibling donor for treatment of myeloid malignancies. <i>Human Immunology</i> , 2016, 77, 861-868.	1.2	8
51	Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. <i>Lancet Haematology</i> , 2016, 3, e581-e591.	2.2	34
52	Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2016, 38, 247-251.	0.7	2
53	Chimerism interpretation with a highly sensitive quantitative PCR method: 6 months median latency before chimerism drop below 0.1%. <i>Bone Marrow Transplantation</i> , 2016, 51, 874-875.	1.3	8
54	Influence of BCR-ABL Transcript Type on Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia Treated with Imatinib 400 Mg. <i>Blood</i> , 2016, 128, 1911-1911.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Patients' perceptions about diagnosis and treatment of chronic myeloid leukemia: a cross-sectional study among Brazilian patients. Sao Paulo Medical Journal, 2015, 133, 471-479.	0.4	4
56	Many thanks to our eternal Editor of the Revista Brasileira de Hematologia e Hemoterapia, Professor Milton Artur Ruiz. Revista Brasileira De Hematologia E Hemoterapia, 2015, 37, 1-2.	0.7	0
57	BCR-ABL1 Transcript Levels at 3 and 6 Months Are Better for Identifying Chronic Myeloid Leukemia Patients with Poor Outcome in Response to Second-Line Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure: A Report from a Single Institution. Acta Haematologica, 2015, 134, 248-254.	0.7	9
58	Publications of bone marrow transplants in Latin America. A report of the Latin American Group of Bone Marrow Transplantation. Bone Marrow Transplantation, 2015, 50, 1130-1131.	1.3	9
59	BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival. Cancer Investigation, 2015, 33, 451-458.	0.6	15
60	Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. British Journal of Haematology, 2015, 168, 69-81.	1.2	177
61	Assessment of Cardiovascular Events in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. Blood, 2015, 126, 4031-4031.	0.6	1
62	Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors – a single center experience. Clinics, 2015, 70, 550-555.	0.6	19
63	Clinical Characteristics and Outcome of 104 Patients with Gastric Diffuse B-Cell Non-Hodgkin Lymphoma (DLBCL) a Multicenter Study. Blood, 2015, 126, 5032-5032.	0.6	0
64	Collagen Fibers Structure Detected By Second-Harmonic Generation Microscopy: A Potential Prognostic Marker for High-Risk Nodular Sclerosis. Blood, 2015, 126, 5000-5000.	0.6	0
65	Pre-Transplant Beta2-Microglobulin Is an Independent Biomarker of Acute Graft-Versus-Host-Disease after Allogeneic Hematopoietic Cell Transplant in a Single Institutional Study. Blood, 2015, 126, 3152-3152.	0.6	0
66	Protein-coding genes and long noncoding RNAs are differentially expressed in dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib. Hematology, 2014, 19, 31-41.	0.7	13
67	Five years of implementation of guidelines in hematology and transfusion medicine in Brazil. Revista Brasileira De Hematologia E Hemoterapia, 2014, 36, 165-166.	0.7	0
68	Improvement in the outcome of invasive fusariosis in the last decade. Clinical Microbiology and Infection, 2014, 20, 580-585.	2.8	151
69	Impairment of thrombin generation in the early phases of the host response of sepsis. Journal of Critical Care, 2014, 29, 31-36.	1.0	16
70	Identification of target genes using gene expression profile of granulocytes from patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Leukemia and Lymphoma, 2014, 55, 1861-1869.	0.6	7
71	Associations of VEGF and VEGFR2 polymorphisms with increased risk and aggressiveness of multiple myeloma. Annals of Hematology, 2014, 93, 1363-9.	0.8	15
72	Quality of life of chronic myeloid leukemia patients in Brazil: ability to work as a key factor. Supportive Care in Cancer, 2014, 22, 2113-8.	1.0	9

#	ARTICLE	IF	CITATIONS
73	Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. <i>Blood</i> , 2014, 123, 1353-1360.	0.6	231
74	Comparison of Diagnostic Tests in Distinct Well-Defined Conditions Related to Dry Eye Disease. <i>PLoS ONE</i> , 2014, 9, e97921.	1.1	77
75	Polymorphism BCL2 c(-717)a and prognosis in diffuse large B-cell lymphoma patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8573-8573.	0.8	0
76	Evaluation of Peroxiredoxins (PRDX1, PRDX2 and PRDX6) Expression in Patients with Chronic Myeloid Leukemia (CML) Treated with Imatinib in First Line. <i>Blood</i> , 2014, 124, 5545-5545.	0.6	0
77	Clinical Characteristics and Outcome of 41 Patients with Upper GI Diffuse B-Cell Non-Hodgkin Lymphoma. Results of Brazilian-Italy Lymphoma Registry. <i>Blood</i> , 2014, 124, 5400-5400.	0.6	0
78	VEGF 2578 c>a, a Functional Angiogenic Polymorphism, Is Associated with Aggressiveness and Clinical Outcome of Follicular Lymphoma. <i>Blood</i> , 2014, 124, 3022-3022.	0.6	0
79	Association of Bax and Bcl-2 polymorphisms in Aggressiveness and Prognosis of Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 3017-3017.	0.6	0
80	Intracranial primary dural diffuse large B-cell lymphoma successfully treated with chemotherapy. <i>International Journal of Clinical and Experimental Medicine</i> , 2014, 7, 456-60.	1.3	9
81	Cytomegalovirus (CMV) genotype in allogeneic hematopoietic stem cell transplantation. <i>BMC Infectious Diseases</i> , 2013, 13, 310.	1.3	23
82	Quantifying loss of CD34+ cells collected by apheresis after processing for freezing and post-thaw. <i>Transfusion and Apheresis Science</i> , 2013, 48, 241-246.	0.5	25
83	A high angiopoietin-2/angiopoietin-1 ratio is associated with a high risk of septic shock in patients with febrile neutropenia. <i>Critical Care</i> , 2013, 17, R169.	2.5	24
84	Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil. <i>Clinical Microbiology and Infection</i> , 2013, 19, 745-751.	2.8	118
85	Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. <i>Annals of Oncology</i> , 2013, 24, 2430-2434.	0.6	89
86	Adherence to Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia: A Brazilian Single-Center Cohort. <i>Acta Haematologica</i> , 2013, 130, 16-22.	0.7	34
87	Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em MolÃ©stias Onco-HematolÃ³gicas retrospective study. <i>Leukemia and Lymphoma</i> , 2013, 54, 53-57.	0.6	42
88	Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions. <i>Hematological Oncology</i> , 2013, 31, 72-78.	0.8	11
89	Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. <i>Blood</i> , 2013, 121, 3703-3708.	0.6	91
90	Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Suboptimal Cytogenetic Response (CyR) On Imatinib: First Results Of The LASOR Trial. <i>Blood</i> , 2013, 122, 95-95.	0.6	2

#	ARTICLE	IF	CITATIONS
91	Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome. Clinics, 2013, 68, 339-343.	0.6	9
92	Evaluation Of hOCT1 expression In Patients With Chronic Myeloid Leukemia (CML) Treated With Imatinib In First Line. Blood, 2013, 122, 4041-4041.	0.6	1
93	Treatment Results With Dasatinib Or Nilotinib In Third Line Therapy Of Chronic Myeloid Leukemia After Failure Of Two Tyrosine Kinase Inhibitors. Blood, 2013, 122, 5189-5189.	0.6	0
94	Multiple Myeloma Profile In Latin America: Clinical and Epidemiological Observational Study. Blood, 2013, 122, 5327-5327.	0.6	1
95	Associations Of VEGF and VEGFR2 Polymorphisms With Increased Risk and Aggressiveness Of Multiple Myeloma. Blood, 2013, 122, 1886-1886.	0.6	0
96	Early Molecular Response Is Predictive Of Overall, Progression-Free and Event-Free Survival In Chronic Myeloid Leukemia Using Second-Generation Tyrosine Kinase Inhibitors After Imatinib Treatment. Blood, 2013, 122, 1326-1326.	0.6	0
97	Evaluation Of Anemia After Long-Term Treatment With Imatinib In Chronic Myeloid Leukemia In Chronic Phase. Blood, 2013, 122, 5200-5200.	0.6	0
98	Predictive Value Of Early Molecular Responses In Outcomes Of Patients With Chronic Myeloid Leukemia Treated With Imatinib In First-Line Therapy. Blood, 2013, 122, 4941-4941.	0.6	1
99	Metabolomic Model For Chronic Gvhd Diagnosis. Blood, 2013, 122, 3304-3304.	0.6	0
100	Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. Haematologica, 2012, 97, 1666-1673.	1.7	110
101	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia, 2012, 26, 149-157.	3.3	664
102	Functional evaluation indicates physical losses after hematopoietic stem cell transplantation. Revista Brasileira De Hematologia E Hemoterapia, 2012, 34, 345-351.	0.7	14
103	Association between human leukocyte antigens and graft-versus-host disease occurrence after allogenic hematopoietic stem cell transplantation. Sao Paulo Medical Journal, 2012, 130, 219-224.	0.4	2
104	Polymorphisms of <i>VEGF</i>, <i>GSTM1</i> and <i>GSTT1</i> genes in multiple myeloma risk. Hematological Oncology, 2012, 30, 105-107.	0.8	5
105	Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma. American Journal of Hematology, 2012, 87, 948-952.	2.0	63
106	Expanding Nilotinib Access in Clinical Trials (ENACT). Cancer, 2012, 118, 118-126.	2.0	61
107	Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients). Blood, 2012, 120, 167-167.	0.6	17
108	EUTOS Score Is Predictive of Event-Free Survival, but Not for Progression-Free and Overall Survival in Patients with Early Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib: A Single Institution Experience. Blood, 2012, 120, 1681-1681.	0.6	4

#	ARTICLE	IF	CITATIONS
109	What is happening with the supply of oncology drugs in Brazil and the world?. Revista Brasileira De Hematologia E Hemoterapia, 2012, 34, 1-2.	0.7	2
110	Philadelphia-negative chronic myeloproliferative neoplasms. Revista Brasileira De Hematologia E Hemoterapia, 2012, 34, 140-149.	0.7	14
111	Evaluation of respiratory conditions in early phase of hematopoietic stem cell transplantation. Revista Brasileira De Hematologia E Hemoterapia, 2012, 34, 188-192.	0.7	14
112	Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012. Revista Brasileira De Hematologia E Hemoterapia, 2012, 34, 367-382.	0.7	7
113	Early Assessment of Molecular Response in Chronic Myeloid Leukemia Patients On Dasatinib After Imatinib Failure Identify Patients with Poor Cytogenetic and Molecular Responses. Blood, 2012, 120, 3787-3787.	0.6	1
114	A High Angiopoietin-2/Angiopoietin-1 Ratio Independently Predicts Septic Shock Development in Patients with Chemotherapy-Associated Febrile Neutropenia and Hematological Malignancies.. Blood, 2012, 120, 2154-2154.	0.6	0
115	The Utilization of NET Promoter System As a Blood Supply Management Strategy. Blood, 2012, 120, 4378-4378.	0.6	0
116	The Relationship Between the Regulation of TOB1 Gene with Cell Proliferation, Apoptosis and Cell Cycle in BCR-ABL Positive Cells. Blood, 2012, 120, 5125-5125.	0.6	0
117	Time-course of sFlt-1 and VEGF-A release in neutropenic patients with sepsis and septic shock: a prospective study. Journal of Translational Medicine, 2011, 9, 23.	1.8	29
118	Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncology, The, 2011, 12, 841-851.	5.1	444
119	Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase. Revista Brasileira De Hematologia E Hemoterapia, 2011, 33, 211-215.	0.7	14
120	Fractal Characteristics of May-Grünwald-Giemsa Stained Chromatin Are Independent Prognostic Factors for Survival in Multiple Myeloma. PLoS ONE, 2011, 6, e20706.	1.1	50
121	Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia. Haematologica, 2011, 96, 134-141.	1.7	85
122	Allogeneic Hematopoietic Stem Cell Transplantation in Paroxysmal Nocturnal Hemoglobinuria: A Transplant Versus No Transplant Matched Comparison Study On Behalf of the Severe Aplastic Anemia Working Party (SAA WP) of the European Group for Blood and Marrow Transplantation (EBMT) Group and the French Society of Hematology (SFH). Blood, 2011, 118, 2403-2403.	0.6	1
123	Importance of killer immunoglobulin-like receptors in allogeneic hematopoietic stem cell transplantation. Revista Brasileira De Hematologia E Hemoterapia, 2011, 33, 126-130.	0.7	3
124	Hematology in Latin America. Revista Brasileira De Hematologia E Hemoterapia, 2011, 33, 449-454.	0.7	5
125	T-Cell Lymphomas in South America and Europe. Revista Brasileira De Hematologia E Hemoterapia, 2011, 34, 42-47.	0.7	38
126	The evolution of drug therapy and the challenges to physicians, patients and healthcare systems. Revista Brasileira De Hematologia E Hemoterapia, 2011, 33, 249-249.	0.7	0

#	ARTICLE	IF	CITATIONS
127	Brazilian experience using high dose sequential chemotherapy followed by autologous hematopoietic stem cell transplantation for malignant lymphomas. Revista Brasileira De Hematologia E Hemoterapia, 2011, 33, 432-438.	0.7	1
128	The evolution of the "Revista Brasileira de Hematologia e Hemoterapia" to meet the challenges of a new era. Revista Brasileira De Hematologia E Hemoterapia, 2011, 33, 1-2.	0.7	4
129	The Incidence of BCR-ABL Mutations and Their Impact on Outcome in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib or Imatinib in ENESTnd: 36-Month Follow-up. Blood, 2011, 118, 2755-2755.	0.6	3
130	Hematopoietic Cell Transplantation Co-Morbidity Index (HCT-CI) to Predict Non Relapse Mortality After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Blood, 2011, 118, 4561-4561.	0.6	2
131	Cytomegalovirus (CMV) gB3 Genotype Is Associated with Acute Gvhd and CMV Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients (HSCT). Blood, 2011, 118, 1958-1958.	0.6	0
132	Evaluation of Thrombin Generation in the Early Stages of Sepsis in Patients with Hematological Malignancies and Febrile Neutropenia,. Blood, 2011, 118, 3347-3347.	0.6	9
133	Bcr-Abl Mutations in Chronic Myeloid Leukemia - Impact on Survival and Treatment with Second Generation Inhibitorsâ€“ A Study on Behalf of Latin American Leukemia Net (Lalnet). Blood, 2011, 118, 1701-1701.	0.6	1
134	The Alteration of SEPT5 Gene Expression in BCR-ABL Positive Cells and Its Possible Correlation with the Development and / or Progression of Chronic Myeloid Leukemia (CML). Blood, 2011, 118, 4415-4415.	0.6	0
135	Valor prognÃ³stico da tomografia computadorizada de seios paranasais no transplante de cÃ©lulas-tronco hematopoiÃ©ticas. Brazilian Journal of Otorhinolaryngology, 2010, 76, 618-622.	0.4	6
136	Current patient management of chronic myeloid leukemia in Latin America. Cancer, 2010, 116, 4991-5000.	2.0	23
137	Surveillance of active human cytomegalovirus infection in hematopoietic stem cell transplantation (HLA sibling identical donor): search for optimal cutoff value by real-time PCR. BMC Infectious Diseases, 2010, 10, 147.	1.3	29
138	Perforin and granzyme B involvement in oral lesions of lichen planus and chronic GVHD. Journal of Oral Pathology and Medicine, 2010, 39, 741-746.	1.4	11
139	Taste disorders and oral evaluation in patients undergoing allogeneic hematopoietic SCT. Bone Marrow Transplantation, 2010, 45, 705-711.	1.3	55
140	Serological monitoring of a Toxoplasma infection after hematopoietic stem cell transplantation. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2010, 52, 225-227.	0.5	5
141	Treatment Outcome of Acute Promyelocytic Leukemia with Modified Aida Protocol. Advances in Hematology, 2010, 2010, 1-3.	0.6	2
142	Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study. Journal of Clinical Oncology, 2010, 28, 424-430.	0.8	265
143	Molecular identification of the HLA-DRB1-DQB1 for diagnosis and follow-up of acute leukemias. Blood Cells, Molecules, and Diseases, 2010, 44, 69-73.	0.6	14
144	High Adherence to Tyrosine Kinase Inhibitors Seems to Be Related to Best Cytogenetic Responso In the Hasford Lower Risk Graup In Chronic Myeloid Leukemia.. Blood, 2010, 116, 4477-4477.	0.6	1

#	ARTICLE	IF	CITATIONS
145	Herpetic geometric glossitis: Acyclovir resistant case in a patient with acute myelogenous leukemia. Indian Journal of Pathology and Microbiology, 2010, 53, 133.	0.1	7
146	O desafio de 2011. Revista Brasileira De Hematologia E Hemoterapia, 2010, 32, 429-429.	0.7	1
147	Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance. Revista Brasileira De Hematologia E Hemoterapia, 2010, 33, 65-72.	0.7	1
148	Oral HPV infection in a bone marrow transplantation patient: a case report with atypical clinical presentation and unexpected outcome. Brazilian Journal of Infectious Diseases, 2010, 14, 89-91.	0.3	4
149	Clinical, Histomorphometric and Radiographic Evaluation of Dental Extraction Sockets Treated with Autologous Stem Cells. Blood, 2010, 116, 2398-2398.	0.6	0
150	Prognostic value of sinus CT scans in hematopoietic stem cell transplantation. Brazilian Journal of Otorhinolaryngology, 2010, 76, 618-22.	0.4	2
151	Transplante de células-tronco hematopoéticas e a regeneração da hematopoese. Revista Brasileira De Hematologia E Hemoterapia, 2009, 31, 280-284.	0.7	0
152	Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial. Journal of Clinical Oncology, 2009, 27, 3472-3479.	0.8	181
153	Skin and oral lesions associated to imatinib mesylate therapy. Supportive Care in Cancer, 2009, 17, 465-468.	1.0	44
154	Brazilian Experience Using High-Dose Sequential Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma. Clinical Lymphoma and Myeloma, 2009, 9, 449-454.	1.4	4
155	New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Leukemia and Lymphoma, 2009, 50, 1148-1154.	0.6	12
156	Impact of Prior Therapy and Suboptimal Response to Imatinib On the Efficacy and Safety of Nilotinib Among 1,422 Patients with Imatinib-Resistant or Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Sub-Analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.. Blood, 2009, 114, 2201-2201.	0.6	5
157	Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access) Tj ETQq1o1e0.7843a4 rgBT		
158	Outcomes After Related and Unrelated Umbilical Cord Blood Transplantation for Congenital Bone Marrow Failure Syndromes Other Than Fanconi Anemia.. Blood, 2009, 114, 2300-2300.	0.6	0
159	The Gene RUNX1 and Its Possible Relation with the Alteration of Granulocytes Cells and with the Progression of Chronic Myeloid Leukemia.. Blood, 2009, 114, 2215-2215.	0.6	0
160	Unrelated Cord Blood Transplantation in Patients with Hematologic Malignancies in Brazil - A Sociedade Brasileira De Transplantes De Medula Ossea and Eurocord Collaborative Study.. Blood, 2009, 114, 1211-1211.	0.6	0
161	Impact of Imatinib Dose Escalation in Chronic Myeloid Leukemia Patients in Chronic Phase with Sub-Optimal Response or Failure with Imatinib 400 Mg.. Blood, 2009, 114, 3289-3289.	0.6	0
162	Gene Expression Profile in Responsive and Non-Responsive Chronic Myeloid Leukemia Patients Treated with Dasatinib.. Blood, 2009, 114, 3260-3260.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical) Tj ETQq1 1 0.784314 rgBT /Over	0.8	10
164	Polymorphisms of methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), methionine synthase reductase (MTRR), and thymidylate synthase (TYMS) in multiple myeloma risk. Leukemia Research, 2008, 32, 401-405.	0.4	32
165	An algorithm based on peripheral CD34+ cells and hemoglobin concentration provides a better optimization of apheresis than the application of a fixed CD34 threshold. Transfusion, 2008, 48, 1133-1137.	0.8	10
166	<i>TNF, IFNG, IL6, IL10</i> and <i>TGFB1</i> gene polymorphisms in South and Southeast Brazil. International Journal of Immunogenetics, 2008, 35, 287-293.	0.8	29
167	Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma. Haematologica, 2008, 93, 791-792.	1.7	34
168	Importância de polimorfismos de genes reguladores de citocinas em transplantes de células progenitoras hematopoiéticas. BJPS: Brazilian Journal of Pharmaceutical Sciences, 2008, 44, 739-748.	0.5	2
169	Papel das citocinas na imunopatogênese da doença do enxerto contra o hospedeiro. Revista Brasileira De Hematologia E Hemoterapia, 2008, 30, .	0.7	4
170	Thalidomide + Dexamethasone as Maintenance after Single Autologous Stem Cell Transplantation Improves Progression-Free Survival (PFS) in Advanced Multiple Myeloma. A Prospective Brazilian Randomized Trial. Blood, 2008, 112, 3703-3703.	0.6	5
171	Correlation of IL-6 and IL-10 production following bone marrow transplantation with donor cytokine gene polymorphisms. Revista Brasileira De Hematologia E Hemoterapia, 2008, 30, .	0.7	1
172	Urgência na introdução do NAT: É fundamental não cometer os erros do passado. Revista Brasileira De Hematologia E Hemoterapia, 2008, 30, .	0.7	1
173	Stem Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria: An on Going Joint Study of the AAWP EBMT Group and the French Society of Hematology. Blood, 2008, 112, 3442-3442.	0.6	1
174	Outcome of Patients with Chronic Myeloid Leukemia with T315I BCR-ABL Mutation. Blood, 2008, 112, 4262-4262.	0.6	0
175	Effect of Panel-Reactive Antibody in Predicting Crossmatch Selection of Cadaveric Kidney Recipients. Transplantation Proceedings, 2007, 39, 429-431.	0.3	10
176	High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma – Results of a comprehensive meta-analysis. Cancer Treatment Reviews, 2007, 33, 338-346.	3.4	80
177	Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood, 2007, 109, 4143-4150.	0.6	352
178	Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplantation, 2007, 39, 775-781.	1.3	145
179	Six cases of leprosy associated with allogeneic hematopoietic SCT. Bone Marrow Transplantation, 2007, 40, 859-863.	1.3	12
180	IL2 and TNFA Gene Polymorphisms and the Risk of Graft-versus-Host Disease after Allogeneic Haematopoietic Stem Cell Transplantation. Scandinavian Journal of Immunology, 2007, 66, 703-710.	1.3	34

#	ARTICLE	IF	CITATIONS
181	Detection of human herpesvirus 6 in patients with oral chronic graft-vs-host disease following allogeneic progenitor cell transplantation. <i>Oral Diseases</i> , 2007, 13, 329-334.	1.5	10
182	GSTM1 and codon 72 P53 polymorphism in multiple myeloma. <i>Annals of Hematology</i> , 2007, 86, 815-819.	0.8	14
183	Screening of Mutations in BCR-ABL Kinase Domain in Chronic Myeloid Leukemia (CML) Patients Treated with Kinase Inhibitors by Denaturing High-Performance Liquid Chromatography (D-HPLC).. <i>Blood</i> , 2007, 110, 4580-4580.	0.6	0
184	Brazilian Experience Using High Dose Sequential (HDS) Followed by Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Relapse/Refractory Aggressive Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2007, 110, 5102-5102.	0.6	0
185	High Dose Sequential (HDS) Followed by Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Salvage Treatment of Hodgkin's Disease (HD): A Brazilian Experience.. <i>Blood</i> , 2007, 110, 5103-5103.	0.6	0
186	Large infiltration of chronic lymphocytic leukemia in the mandibular region. <i>Oral Oncology</i> , 2006, 42, 49-51.	0.7	2
187	Optimization of CD34+ collection for autologous transplantation using the evolution of peripheral blood cell counts after mobilization with chemotherapy and G-CSF. <i>Transfusion and Apheresis Science</i> , 2006, 34, 33-40.	0.5	10
188	Comparison of serology, antigenemia assay and the polymerase chain reaction for monitoring active cytomegalovirus infections in hematopoietic stem cell transplantation patients. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2006, 48, 275-278.	0.5	8
189	DECH crônica: fator preditivo para rinossinite no transplante de medula Óssea. <i>Revista Brasileira De Otorrinolaringologia</i> , 2006, 72, 328-332.	0.2	3
190	Major salivary gland damage in allogeneic hematopoietic progenitor cell transplantation assessed by scintigraphic methods. <i>Bone Marrow Transplantation</i> , 2006, 37, 955-959.	1.3	23
191	Risk factors and characteristics of ocular complications, and efficacy of autologous serum tears after haematopoietic progenitor cell transplantation. <i>Bone Marrow Transplantation</i> , 2006, 38, 223-227.	1.3	52
192	Frontline Therapy with Early Intensification and Autologous Stem Cell Transplantation versus Conventional Chemotherapy in Unselected High-Risk, Aggressive Non-Hodgkin's Lymphoma Patients: A Prospective Randomized GEMOH Report. <i>Acta Haematologica</i> , 2006, 115, 15-21.	0.7	14
193	Detection of BCR-ABL Point Mutations in Patients with Chronic Myeloid Leukemia (CML) Resistant to Imatinib.. <i>Blood</i> , 2006, 108, 4817-4817.	0.6	0
194	Characterization of Gene Expression Profiles of Plasma Cells in Patients with Multiple Myeloma.. <i>Blood</i> , 2006, 108, 5082-5082.	0.6	0
195	Surveillance of cytomegalovirus infection in haematopoietic stem cell transplantation patients. <i>Journal of Infection</i> , 2005, 50, 130-137.	1.7	24
196	The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. <i>Bone Marrow Transplantation</i> , 2005, 36, 1043-1047.	1.3	39
197	Late effects of chronic graft-vs.-host disease in minor salivary glands. <i>Journal of Oral Pathology and Medicine</i> , 2005, 34, 486-493.	1.4	38
198	Polymorphisms of glutathione S-transferase mu1 (GSTM1) and theta 1 (GSTT1) genes in chronic myeloid leukaemia. <i>European Journal of Haematology</i> , 2005, 75, 530-531.	1.1	19

#	ARTICLE	IF	CITATIONS
199	Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol. Sao Paulo Medical Journal, 2005, 123, 266-270.	0.4	1
200	AssociaÃ§Ã£o dos nÃveis de citocinas no pÃ³s-transplante de cÃ©lulas-tronco hematopoiÃ©ticas com a DoenÃ§a do Enxerto Contra o Hospedeiro aguda. Revista Brasileira De Hematologia E Hemoterapia, 2005, 27, 166.	0.7	0
201	Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG. Annals of Oncology, 2005, 16, 1941-1948.	0.6	37
202	Relationship between cytokine gene polymorphisms and graft-versus-host disease after allogeneic stem cell transplantation in a Brazilian population. Cytokine, 2005, 32, 171-177.	1.4	36
203	Aggressive Non-Hodgkin's Lymphoma: therapeutic considerations of pre rituximab era. Brazilian Journal of Infectious Diseases, 2005, 9, 439-441.	0.3	0
204	High-Dose Sequential Chemotherapy Versus a Less Intensive Chemotherapeutic Regimen Followed by Peripheral Blood Progenitor Cell Autografting in Patients with Advanced Hodgkin's Disease.. Blood, 2005, 106, 5485-5485.	0.6	0
205	Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant outcome. Haematologica, 2005, 90, 232-7.	1.7	19
206	A psychosocial assessment interview of candidates for hematopoietic stem cell transplantation. Haematologica, 2005, 90, 570-2.	1.7	5
207	Os desafios no tratamento da Leucemia mielÃ³ide crÃ³nica na era do mesilato de imatinibe. Revista Brasileira De Hematologia E Hemoterapia, 2004, 26, 282.	0.7	0
208	Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection. Bone Marrow Transplantation, 2004, 33, 9-13.	1.3	40
209	Effects of high platelet concentration in collecting and freezing dry platelets concentrates. Transfusion and Apheresis Science, 2004, 30, 205-212.	0.5	12
210	Inherited Mutation in Exon 2 of GATA-1 Is Associated with a Clinical and Laboratory Picture Similar to Familial Hypocellular Myelodysplastic Syndrome (MDS).. Blood, 2004, 104, 3432-3432.	0.6	1
211	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) - EBMT Risk Score Evaluation for Chronic Myeloid Leukemia in Brazil.. Blood, 2004, 104, 3334-3334.	0.6	0
212	A possible role of the P53 gene deletion as a prognostic factor in multiple myeloma. Annals of Hematology, 2003, 82, 405-409.	0.8	5
213	Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer, 2003, 98, 315-319.	2.0	270
214	The expression of PRAME in chronic lymphoproliferative disorders. Leukemia Research, 2003, 27, 393-396.	0.4	26
215	Primary aspergillosis affecting the tongue of a leukemic patient. Oral Diseases, 2003, 9, 49-53.	1.5	11
216	Infectious complications in patients randomized to receive allogeneic bone marrow or peripheral blood transplantation. Transplant Infectious Disease, 2003, 5, 167-173.	0.7	40

#	ARTICLE	IF	CITATIONS
217	The Prognostic Relevance of Apoptosis-related Proteins in Classical Hodgkin's Lymphomas. <i>Leukemia and Lymphoma</i> , 2003, 44, 483-488.	0.6	23
218	Expression of p190 BCR-ABL fusion gene in a patient with chronic myeloid leukemia. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2003, 25, 173.	0.7	2
219	Serum cytokine levels and acute graft-versus-host disease after HLA-identical hematopoietic stem cell transplantation. <i>Experimental Hematology</i> , 2003, 31, 1044-1050.	0.2	41
220	Addition of exogenous cytokines in mixed lymphocyte culture for selecting related donors for bone marrow transplantation. <i>Sao Paulo Medical Journal</i> , 2002, 120, 175-179.	0.4	0
221	Further remarks on the expression of CD20 in classical Hodgkin's lymphomas. <i>Haematologica</i> , 2002, 87, ELT17.	1.7	6
222	Quality of life in patients randomized to receive a bone marrow or a peripheral blood allograft. <i>Haematologica</i> , 2002, 87, 1281-5.	1.7	13
223	Blood group genotyping in a population of highly diverse ancestry. <i>Journal of Clinical Laboratory Analysis</i> , 2001, 15, 8-13.	0.9	21
224	Iron deficiency and protection of blood donors. <i>Sao Paulo Medical Journal</i> , 2001, 119, 131-131.	0.4	1
225	Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: a retrospective study. <i>British Journal of Haematology</i> , 2000, 110, 300-307.	1.2	55
226	Early total white blood cell recovery is a predictor of low number of apheresis and good CD34+ cell yield. <i>Transfusion Science</i> , 2000, 23, 91-100.	0.6	15
227	Conventional chemotherapy for acute myeloid leukemia: a Brazilian experience. <i>Sao Paulo Medical Journal</i> , 2000, 118, 173-178.	0.4	15
228	Vanishing bile duct syndrome in Hodgkin's disease: case report. <i>Sao Paulo Medical Journal</i> , 2000, 118, 154-157.	0.4	22
229	Múltiplas infecções oportunistas em um paciente com leucemia linfocítica crônica tratado com cladribina. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2000, 22, 420.	0.7	0
230	Osteolytic lesions as a presenting sign of acute myeloid leukemia. <i>Haematologia</i> , 2000, 30, 325-331.	0.2	11
231	GVHD dry eyes treated with autologous serum tears. <i>Bone Marrow Transplantation</i> , 2000, 25, 1101-1103.	1.3	114
232	High-Dose Cyclophosphamide Followed by Autografting Can Improve the Outcome of Relapsed or Resistant Non-Hodgkin's Lymphomas with Involved or Hypoplastic Bone Marrow. <i>Leukemia and Lymphoma</i> , 1999, 33, 321-330.	0.6	10
233	A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. <i>Bone Marrow Transplantation</i> , 1998, 22, 1145-1151.	1.3	178
234	VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. <i>Journal of Clinical Oncology</i> , 1998, 16, 2796-2802.	0.8	204

#	ARTICLE	IF	CITATIONS
235	Immunoglobulin levels in workers exposed to hexachlorobenzene. Human and Experimental Toxicology, 1998, 17, 172-175.	1.1	20
236	Lymphoblastic transformation of myelodysplastic syndrome. Sao Paulo Medical Journal, 1997, 115, 1508-1512.	0.4	9
237	Hemophagocytic syndrome: pitfalls in its diagnosis. Sao Paulo Medical Journal, 1997, 115, 1548-1552.	0.4	5
238	Micronucleus monitoring to assess human occupational exposure to organochlorides. , 1997, 29, 46-52.		48
239	Prevalence of HIV and Treponema pallidum infections in pregnant women in Campinas and their association with socio-demographic factors. Sao Paulo Medical Journal, 1996, 114, 1108-1116.	0.4	11
240	Acute Megakaryoblastic Leukemia: Importance of Bone Marrow Biopsy in Diagnosis. Leukemia and Lymphoma, 1991, 4, 75-79.	0.6	3
241	O transplante de células-tronco hematopoéticas no tratamento dos linfomas não Hodgkin. Revista Brasileira De Hematologia E Hemoterapia, 0, 32, 106-114.	0.7	0